Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators

Journal of Clinical Epidemiology

Volumn 90, Issue , 2017, Pages 92-98

  Zuidgeest, Mira G P ^a   Welsing, Paco M J ^a   van Thiel, Ghislaine J M W ^a   Ciaglia, Antonio ^b   Alfonso Cristancho, Rafael ^c   Eckert, Laurent ^d   Eijkemans, Marinus J C ^a   Egger, Matthias ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b International Alliance of Patients Organizations   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d SANOFI   (France)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

Comparator choice; Pragmatic trial; Real world evidence; Routine clinical practice; Treatment strategy; Usual care

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPARATIVE STUDY; DATA ANALYSIS; DRUG THERAPY; HEALTH CARE; HUMAN; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; DECISION MAKING; EVIDENCE BASED MEDICINE; INFORMATION PROCESSING; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

DATA COLLECTION; DECISION MAKING; DRUG THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRAGMATIC CLINICAL TRIALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85028048869     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2017.07.001     Document Type: Article

References (42)

1. Schwartz, D., Lellouch, J., Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 62 (2009), 499–505.
2. Treweek, S., Zwarenstein, M., Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials, 10, 2009, 37.
3. Tunis, S.R., Stryer, D.B., Clancy, C.M., Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290 (2003), 1624–1632.
4. Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K.E., Zwarenstein, M., The PRECIS-2 tool: designing trials that are fit for purpose. BMJ, 350, 2015, h2147.
5. Jönsson, B., Relative effectiveness and the European pharmaceutical market. Eur J Health Econ 12 (2011), 97–102.
6. Thorpe, K.E., Zwarenstein, M., Oxman, A.D., Treweek, S., Furberg, C.D., Altman, D.G., et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 180 (2009), E47–E57.
7. Zuidgeest, M.G., Goetz, I., Grobbee, D.E., WP3 of the GetReal Consortium. PRECIS-2 in perspective: what is next for pragmatic trials?. J Clin Epidemiol 84 (2017), 22–24.
8. Chokshi, D.A., Avorn, J., Kesselheim, A.S., Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood) 29 (2010), 1842–1848.
9. ICE E10 Choice of Control Group in Clinical Trials. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002925.pdf. Accessed July 24, 2017.
10. Kaul, S., Diamond, G.A., Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 145 (2006), 62–69.
11. Torrance, G.W., Drummond, M.F., Walker, V., Switching therapy in health economics trials: confronting the confusion. Med Decis Making 23 (2003), 335–340.
12. Methodological guideline for REA of pharmaceuticals: Criteria for the choice of the most appropriate comparator(s) | EUnetHTA. Available at http://www.eunethta.eu/outputs/methodological-guideline-rea-pharmaceuticals-criteria-choice-most-appropriate-comparators. Accessed July 24, 2017.
13. Kalkman, S., van Thiel, G.J.M.W., Grobbee, D.E., van Delden, J.J.M., Pragmatic randomized trials in drug development pose new ethical questions: a systematic review. Drug Discov Today 20 (2015), 856–862.
14. Smelt, A.F.H., Van Der Week, G.M., Blom, J.W., Gussekloo, J., Assendelft, W.J.J., How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract 60 (2010), e305–e318.
15. Weinberger, M., Oddone, E.Z., Henderson, W.G., Smith, D.M., Huey, J., Giobbie-Hurder, A., et al. Multisite randomized controlled trials in health services research: scientific challenges and operational issues. Med Care 39 (2001), 627–634.
16. Beghi, E., Randomised controlled monotherapy trials: which comparators to use?. Epileptic Disord 14 (2012), 235–241.
17. Freedman, B., Equipoise and the ethics of clinical research. N Engl J Med 317 (1987), 141–145.
18. Resnik, D.B., The clinical investigator-subject relationship: a contextual approach. Philos Ethics, Humanit Med, 4, 2009, 16.
19. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310 (2013), 2191–2194.
20. Kim, S.Y.H., Miller, F.G., Ethical complexities in standard of care randomized trials: a case study of morning versus nighttime dosing of blood pressure drugs. Clin Trials 12 (2015), 557–563.
21. Kleijnen, S., George, E., Goulden, S., d'Andon, A., Vitré, P., Osińska, B., et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value Health 15 (2012), 954–960.
22. Mathes, T., Jacobs, E., Morfeld, J.-C., Pieper, D., Methods of international health technology assessment agencies for economic evaluations—a comparative analysis. BMC Health Serv Res 13 (2013), 1–10.
23. Juni, P., Altman, D.G., Egger, M., Systematic reviews in health care: assessing the quality of controlled clinical trials. Br Med J 323 (2001), 42–46.
24. Schulz, K.F., Chalmers, I., Hayes, R.J., Altman, D., Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995), 408–412.
25. Little, P., Moore, M., Kelly, J., Williamson, I., Leydon, G., McDermott, L., et al. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ, 347, 2013, f6041.
26. Mastellos, N., Bliźniuk, G., Czopnik, D., McGilchrist, M., Misiaszek, A., Bródka, P., et al. Feasibility and acceptability of TRANSFoRm to improve clinical trial recruitment in primary care. Fam Pract 33 (2016), 186–191.
27. Puffer, S., Torgerson, D., Watson, J., Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ 327 (2003), 785–789.
28. Campbell, M.K., Piaggio, G., Elbourne, D.R., Altman, D.G., Consort 2010 statement: extension to cluster randomised trials. BMJ, 345, 2012, e5661.
29. van der Graaf, R., Koffijberg, H., Grobbee, D.E., de Hoop, E., Moons, K.G.M., van Thiel, G.J.M.W., et al. The ethics of cluster-randomized trials requires further evaluation: a refinement of the Ottawa Statement. J Clin Epidemiol 68 (2015), 1108–1114.
30. Harrison, J.D., Solomon, M.J., Young, J.M., Meagher, A., Butow, P., Salkeld, G., et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg 143 (2008), 389–394.
31. Bradley, C., Designing medical and educational intervention studies. A review of some alternatives to conventional randomized controlled trials. Diabetes Care 16 (1993), 509–518.
32. Von Essen, L., Non-standard and preference designs. Richards, D., Rahm Hallberg, I., (eds.) Complex interventions in health. An overview of research methods, 2015, Routledge, Abingdon.
33. Brewin, C., Bradley, C., Patient preferences and randomised trials. Br Med J 299 (1989), 313–315.
34. Torgerson, D.J., Sibbald, B., Understanding controlled trials. What is a patient preference trial?. BMJ, 316, 1998, 360.
35. Iyengar, R.N., Balagere, D.S., Henderson, R.R., LeFrancois, A.L., Rabbitt, R.M., Frazee, S.G., Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol. J Manag Care Spec Pharm 20 (2014), 851–861.
36. Zuidgeest, M.G.P., Goetz, I., Groenwold, R.H.H., Irving, E., van Thiel, G.J.M.W., Grobbee, D.E., Pragmatic trials and real world evidence: Paper 1. Introduction. J Clin Epidemiol 88 (2017), 7–13.
37. Patterson, M.E., Blalock, S.J., Smith, A.J., Murray, M.D., Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older. Clin Ther 33 (2011), 608–616.
38. Peduzzi, P., Wittes, J., Detre, K., Holford, T., Analysis as-randomized and the problem of non-adherence: an example from the veterans affairs randomized trial of coronary artery bypass surgery. Stat Med 12 (1993), 1185–1195.
39. Kane, J.M., Dose selection and comparator drugs in schizophrenia research. J Clin Psychiatry 62 Suppl 9 (2001), 29–32 4.
40. Hollis, S., Campbell, F., What is meant by intention to treat analysis? Survey of published randomised controlled trials. Br Med J 319 (1999), 670–674.
41. Zwarenstein, M., Treweek, S., Gagnier, J.J., Altman, D.G., Tunis, S., Haynes, B., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ, 337, 2008, a2390.
42. Ratner, J., Mullins, D., Buesching, D.P., Cantrell, R.A., Pragmatic clinical trials: U.S. payers' views on their value. Am J Manag Care 19 (2013), e158–e165.